Chris Bangma

Summary

Affiliation: Erasmus MC
Country: The Netherlands

Publications

  1. ncbi Gene therapy in urology: strategies to translate theory into practice
    Chris H Bangma
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    BJU Int 96:1163-70. 2005
  2. ncbi PSA level changes over time in men with an initial PSA level of < or = 4 ng/ml
    Chris Bangma
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Nat Clin Pract Urol 3:520-1. 2006
  3. doi Active surveillance for low-risk prostate cancer
    Chris H Bangma
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Crit Rev Oncol Hematol 85:295-302. 2013
  4. doi Defining and predicting indolent and low risk prostate cancer
    Chris H Bangma
    Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Crit Rev Oncol Hematol 83:235-41. 2012
  5. doi The Prostate cancer Research International: Active Surveillance study
    Chris H Bangma
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Curr Opin Urol 22:216-21. 2012
  6. ncbi The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer
    C H Bangma
    Department of Urology, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    BJU Int 93:720-4. 2004
  7. pmc Overdiagnosis and overtreatment of early detected prostate cancer
    C H Bangma
    Department of Urology, Erasmus University Medical Centre, PO Box 2040, 3000 DR Rotterdam, Netherlands
    World J Urol 25:3-9. 2007
  8. ncbi Predictive models in diagnosing indolent cancer
    Chris H Bangma
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer 115:3100-6. 2009
  9. doi Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial
    Madelon N M van der Aa
    Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    J Urol 183:76-80. 2010
  10. pmc Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results
    Shafak Aluwini
    Department of Radiation Oncology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk, Rotterdam, The Netherlands
    Radiat Oncol 8:84. 2013

Detail Information

Publications14

  1. ncbi Gene therapy in urology: strategies to translate theory into practice
    Chris H Bangma
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    BJU Int 96:1163-70. 2005
  2. ncbi PSA level changes over time in men with an initial PSA level of < or = 4 ng/ml
    Chris Bangma
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Nat Clin Pract Urol 3:520-1. 2006
  3. doi Active surveillance for low-risk prostate cancer
    Chris H Bangma
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Crit Rev Oncol Hematol 85:295-302. 2013
    ....
  4. doi Defining and predicting indolent and low risk prostate cancer
    Chris H Bangma
    Department of Urology, Erasmus Medical Centre, Rotterdam, The Netherlands
    Crit Rev Oncol Hematol 83:235-41. 2012
    ..The ultimate value of nomograms for the urologic practice can only be assessed by analysing their practical implementation...
  5. doi The Prostate cancer Research International: Active Surveillance study
    Chris H Bangma
    Department of Urology, Erasmus MC, Rotterdam, The Netherlands
    Curr Opin Urol 22:216-21. 2012
    ..To inform readers on the ongoing activities of the Prostate cancer Research International: Active Surveillance (PRIAS) study in the light of current findings and research problems on active surveillance worldwide...
  6. ncbi The value of (-7, -5)pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer
    C H Bangma
    Department of Urology, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands
    BJU Int 93:720-4. 2004
    ....
  7. pmc Overdiagnosis and overtreatment of early detected prostate cancer
    C H Bangma
    Department of Urology, Erasmus University Medical Centre, PO Box 2040, 3000 DR Rotterdam, Netherlands
    World J Urol 25:3-9. 2007
    ..Men with prostate cancer that is likely to be indolent may be offered active surveillance. Evaluation of active surveillance studies and validation of new biological parameters for risk assessment are expected...
  8. ncbi Predictive models in diagnosing indolent cancer
    Chris H Bangma
    Department of Urology, Erasmus Medical Center, Rotterdam, The Netherlands
    Cancer 115:3100-6. 2009
    ..Those nomograms based on screening series of the general population need further validation before generalized application is feasible. Cancer 2009;115(13 suppl):3100-6. (c) 2009 American Cancer Society...
  9. doi Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial
    Madelon N M van der Aa
    Department of Pathology, Erasmus Medical Center Rotterdam, Rotterdam, The Netherlands
    J Urol 183:76-80. 2010
    ..We evaluated the influence of knowledge of urine test outcome on the accuracy of cystoscopy (diagnostic review bias) during surveillance in patients with low grade, nonmuscle invasive urothelial carcinoma...
  10. pmc Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results
    Shafak Aluwini
    Department of Radiation Oncology, Erasmus MC Daniel den Hoed Cancer Center, Groene Hilledijk, Rotterdam, The Netherlands
    Radiat Oncol 8:84. 2013
    ..This hypofractionation can also be achieved with stereotactic body radiotherapy (SBRT). We report results on toxicity, PSA response, and quality of life (QOL) in patients treated with SBRT for favorable-risk PC...
  11. doi Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After Radical Therapy for Prostate Canc
    Fritz Schröder
    Erasmus Medical Centre, Rotterdam, The Netherlands
    Eur Urol 63:779-87. 2013
    ..This biochemical recurrence typically predates clinically detectable metastatic disease by several years. Management of patients with biochemical recurrence is controversial...
  12. doi CyberKnife stereotactic radiotherapy as monotherapy for low- to intermediate-stage prostate cancer: early experience, feasibility, and tolerance
    Shafak Aluwini
    Department of Radiation Oncology, Daniel den Hoed Cancer Center, Rotterdam, The Netherlands
    J Endourol 24:865-9. 2010
    ..It is a very suitable device for performing hypofractionated stereotactic body radiotherapy as monotherapy for low- to intermediate-risk prostate cancer patients. We report our early experience using this technique...
  13. ncbi Microsatellite analysis of voided-urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: feasibility and clinical utility in a prospective multicenter study (Cost-Effectiveness of Follow-Up of Urinary Bladder Cancer trial [C
    Madelon N M van der Aa
    Department of Pathology, Erasmus MC, Rotterdam, The Netherlands
    Eur Urol 55:659-67. 2009
    ..Microsatellite analysis (MA) of voided-urine samples has been promoted as an alternative for cystoscopy surveillance (UCS) of patients with low-grade non-muscle-invasive papillary urothelial carcinoma (UC)...
  14. ncbi Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening
    Patrik Finne
    Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland
    Int J Cancer 111:310-5. 2004
    ..718). A multivariate algorithm can be used to reduce unnecessary prostate biopsies in screening more effectively than the proportion of free PSA alone, but the algorithms will require updating when clinical practice develops with time...